淀粉样蛋白聚集的磺胺抑制剂:治疗神经退行性疾病的一个有希望的途径。

IF 3.4 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-09-01 DOI:10.1002/cmdc.202500324
Joana Smirnovienė, Daumantas Matulis
{"title":"淀粉样蛋白聚集的磺胺抑制剂:治疗神经退行性疾病的一个有希望的途径。","authors":"Joana Smirnovienė, Daumantas Matulis","doi":"10.1002/cmdc.202500324","DOIUrl":null,"url":null,"abstract":"<p><p>Protein amyloid aggregation is a critical pathological process implicated in nearly 50 amyloid-related diseases, including Alzheimer's and Parkinson's diseases. This review highlights the potential of sulfonamides, a versatile class of compounds recognized for their diverse pharmacological properties, as modulators of protein aggregation. We provide an overview of studies examining the efficacy of sulfonamide derivatives in inhibiting the aggregation of various amyloidogenic proteins, including amyloid-beta, tau, alpha-synuclein, insulin, and transthyretin. In vitro assays, such as Thioflavin T fluorescence and high-resolution imaging techniques, have shown that certain sulfonamides can significantly inhibit fibril formation and promote the stabilization of non-aggregated protein states. The potential for sulfonamides to serve as multi-target agents offers new avenues for therapeutic development. By integrating findings from current research, we support a proposal that sulfonamide-based compounds could play a pivotal role in addressing the multifaceted nature of amyloid-related neurodegenerative diseases, paving the way for innovative therapeutic strategies.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500324"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sulfonamide Inhibitors of Amyloid Aggregation: A Promising Path against Neurodegenerative Diseases.\",\"authors\":\"Joana Smirnovienė, Daumantas Matulis\",\"doi\":\"10.1002/cmdc.202500324\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Protein amyloid aggregation is a critical pathological process implicated in nearly 50 amyloid-related diseases, including Alzheimer's and Parkinson's diseases. This review highlights the potential of sulfonamides, a versatile class of compounds recognized for their diverse pharmacological properties, as modulators of protein aggregation. We provide an overview of studies examining the efficacy of sulfonamide derivatives in inhibiting the aggregation of various amyloidogenic proteins, including amyloid-beta, tau, alpha-synuclein, insulin, and transthyretin. In vitro assays, such as Thioflavin T fluorescence and high-resolution imaging techniques, have shown that certain sulfonamides can significantly inhibit fibril formation and promote the stabilization of non-aggregated protein states. The potential for sulfonamides to serve as multi-target agents offers new avenues for therapeutic development. By integrating findings from current research, we support a proposal that sulfonamide-based compounds could play a pivotal role in addressing the multifaceted nature of amyloid-related neurodegenerative diseases, paving the way for innovative therapeutic strategies.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202500324\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500324\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500324","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

淀粉样蛋白聚集是涉及近50种淀粉样蛋白相关疾病的关键病理过程,包括阿尔茨海默病和帕金森病。这篇综述强调了磺胺类化合物作为蛋白质聚集调节剂的潜力,磺胺类化合物是一类因其多种药理特性而被认可的多用途化合物。我们概述了磺胺衍生物在抑制各种淀粉样蛋白聚集方面的研究,包括淀粉样蛋白- β、tau、α -突触核蛋白、胰岛素和甲状腺转甲状腺素。体外实验,如Thioflavin T荧光和高分辨率成像技术,已经表明某些磺胺类药物可以显著抑制原纤维的形成,促进非聚集蛋白状态的稳定。磺胺类药物作为多靶点药物的潜力为治疗发展提供了新的途径。通过整合目前的研究结果,我们支持基于磺胺的化合物可能在解决淀粉样蛋白相关神经退行性疾病的多面性方面发挥关键作用的建议,为创新的治疗策略铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sulfonamide Inhibitors of Amyloid Aggregation: A Promising Path against Neurodegenerative Diseases.

Protein amyloid aggregation is a critical pathological process implicated in nearly 50 amyloid-related diseases, including Alzheimer's and Parkinson's diseases. This review highlights the potential of sulfonamides, a versatile class of compounds recognized for their diverse pharmacological properties, as modulators of protein aggregation. We provide an overview of studies examining the efficacy of sulfonamide derivatives in inhibiting the aggregation of various amyloidogenic proteins, including amyloid-beta, tau, alpha-synuclein, insulin, and transthyretin. In vitro assays, such as Thioflavin T fluorescence and high-resolution imaging techniques, have shown that certain sulfonamides can significantly inhibit fibril formation and promote the stabilization of non-aggregated protein states. The potential for sulfonamides to serve as multi-target agents offers new avenues for therapeutic development. By integrating findings from current research, we support a proposal that sulfonamide-based compounds could play a pivotal role in addressing the multifaceted nature of amyloid-related neurodegenerative diseases, paving the way for innovative therapeutic strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信